( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Zoladex (Goserelin Acetate Implant) in the Treatment of Endometriosis: A Randomized Comparison With Danazol
Objective : To compare the efficacy , endocrine effects , and safety of Zoladex ( goserelin acetate ) and danazol in the treatment of premenopausal women with endometriosis in a multicenter , r and omized , open study . Methods : Three hundred fifteen patients with stages I-IV endometriosis ( revised American Fertility Society [ AFS ] classification ) were treated with Zoladex , 3.6 mg every 28 days by subcutaneous injection , or danazol , 400 mg orally twice daily for 24 weeks . Efficacy was assessed by determination of pelvic signs and symptoms scores and revised AFS endometriosis scores . Endocrine effects were determined by measurements of hormone levels . Safety was evaluated by physical examination , laboratory indices , occurrence of adverse events , and bone mineral density changes . Results : Both treatments significantly ( P < .0001 ) reduced mean subjective signs and symptoms scores both during and after therapy . The mean percent reduction in the revised AFS endometriosis score after 24 weeks of treatment was 53 % for Zoladex and 33 % for danazol , and reduction in the endometrial implants score was 56 % for Zoladex and 46 % for danazol .  Serum estradiol levels decreased to the postmenopausal range in the Zoladex group and to the early follicular phase range in the danazol group . Hypoestrogenic effects occurred more frequently with Zoladex , whereas and rogenic side effects were more common with danazol . There was a higher percentage of withdrawals due to adverse events with danazol than with Zoladex .  Mean bone mineral density decreased from baseline by 5.4 % in the Zoladex group and increased by 1.0 % in the danazol group at the end of treatment . Conclusion : Zoladex is as well tolerated and as effective as danazol in the treatment of premenopausal women with endometriosis
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .